Wonbiogen Co., Ltd. (KOSDAQ:307280)
South Korea
· Delayed Price · Currency is KRW 1,050.00
-16.00 (-1.50%)
At close: Mar 28, 2025, 3:30 PM KST
Wonbiogen Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 30,440 | 29,615 | 26,748 | 17,721 | 12,018 |
| Other Revenue | -0 | -0 | -0 | -0 | - |
| Revenue | 30,440 | 29,615 | 26,748 | 17,721 | 12,018 |
| Revenue Growth (YoY) | 2.79% | 10.72% | 50.94% | 47.46% | - |
| Cost of Revenue | 16,202 | 15,469 | 14,325 | 10,173 | 7,237 |
| Gross Profit | 14,238 | 14,146 | 12,423 | 7,548 | 4,780 |
| Selling, General & Admin | 6,548 | 5,719 | 5,950 | 4,048 | 1,569 |
| Research & Development | 838.47 | 504.15 | 492.1 | 584.71 | 488.8 |
| Other Operating Expenses | 49.15 | 39.04 | 36.97 | 55.85 | 28.27 |
| Operating Expenses | 8,022 | 7,108 | 7,372 | 5,508 | 2,288 |
| Operating Income | 6,216 | 7,038 | 5,050 | 2,040 | 2,492 |
| Interest Expense | -57.77 | -116.68 | -1,274 | -430.65 | -665.21 |
| Interest & Investment Income | 304.07 | 279.71 | 128.25 | 47 | 7.09 |
| Earnings From Equity Investments | 42.83 | -60.51 | - | - | - |
| Currency Exchange Gain (Loss) | 150.8 | 49.99 | -44.9 | 42.36 | -3.49 |
| Other Non Operating Income (Expenses) | -3.03 | -74.84 | -4.82 | -2,436 | -13,113 |
| EBT Excluding Unusual Items | 6,653 | 7,115 | 3,855 | -737.83 | -11,282 |
| Gain (Loss) on Sale of Investments | -32.64 | 48.67 | -200 | - | - |
| Gain (Loss) on Sale of Assets | -1.38 | -7.13 | 11.69 | -57.7 | - |
| Asset Writedown | -196.65 | - | - | - | - |
| Pretax Income | 6,422 | 7,157 | 3,667 | -795.53 | -11,282 |
| Income Tax Expense | 1,084 | 1,196 | 394.35 | -135.74 | 380.31 |
| Earnings From Continuing Operations | 5,339 | 5,961 | 3,272 | -659.78 | -11,662 |
| Minority Interest in Earnings | 350.98 | -463.77 | -66.38 | -56.42 | - |
| Net Income | 5,690 | 5,497 | 3,206 | -716.2 | -11,662 |
| Net Income to Common | 5,690 | 5,497 | 3,206 | -716.2 | -11,662 |
| Net Income Growth | 3.50% | 71.46% | - | - | - |
| Shares Outstanding (Basic) | 36 | 35 | 36 | 34 | 23 |
| Shares Outstanding (Diluted) | 36 | 38 | 36 | 35 | 23 |
| Shares Change (YoY) | -6.20% | 5.38% | 3.58% | 49.52% | - |
| EPS (Basic) | 160.00 | 157.00 | 90.15 | -20.87 | -502.03 |
| EPS (Diluted) | 160.00 | 145.00 | 89.00 | -21.00 | -503.00 |
| EPS Growth | 10.35% | 62.92% | - | - | - |
| Free Cash Flow | 8,201 | 3,189 | -711.95 | -1,254 | 118.77 |
| Free Cash Flow Per Share | 230.62 | 84.12 | -19.79 | -36.10 | 5.11 |
| Dividend Per Share | - | - | 10.000 | - | - |
| Gross Margin | 46.77% | 47.77% | 46.44% | 42.59% | 39.78% |
| Operating Margin | 20.42% | 23.76% | 18.88% | 11.51% | 20.74% |
| Profit Margin | 18.69% | 18.56% | 11.99% | -4.04% | -97.05% |
| Free Cash Flow Margin | 26.94% | 10.77% | -2.66% | -7.08% | 0.99% |
| EBITDA | 7,863 | 8,607 | 6,249 | 2,921 | 3,223 |
| EBITDA Margin | 25.83% | 29.06% | 23.36% | 16.48% | 26.82% |
| D&A For EBITDA | 1,647 | 1,569 | 1,199 | 881.58 | 731.27 |
| EBIT | 6,216 | 7,038 | 5,050 | 2,040 | 2,492 |
| EBIT Margin | 20.42% | 23.76% | 18.88% | 11.51% | 20.74% |
| Effective Tax Rate | 16.87% | 16.71% | 10.75% | - | - |
| Advertising Expenses | 1,113 | 881.91 | 1,184 | 700.07 | -4.3 |
Updated Nov 11, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.